IgA nephropathy: open trials in China

52 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT06963827
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Trial Treatment · Phase 3 · Takeda
The First Affiliated Hospital of Baotou Medical College, Baotou · Peking University First Hospital, Beijing · Beijing Tsinghua Changgung Hospital, Changping · The Third Xiangya Hospital of Central South University Yuelu District, Changsha · Sichuan Academy of Medical Sciences sichuan Provincial People's Hospital, Chengdu · West China Hospital，Sichuan University, Chengdu · The First Affiliated Hospital of Sun Yat-sen University, Guangdong · Guangdong General Hospital, Guangzhou · The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou · Shandong University Qilu Hospital, Jinan · The First Affiliated Hospital of NanChang University, Nanchang · Zhongda Hospital Southeast University, Nanjing · Affiliated Hospital of Nantong University, Nantong · The First Affiliated Hospital of Ningbo University, Ningbo · Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch, Shanghai · Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai · Peking University Shenzhen Hospital, Shenzhen · Wuxi People's Hospital, Wuxi · Zhongshan Hospital Xiamen University, Xiamen · The Second People's Hospital of Yibin, Yibin · Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai
Registry updated 2026-11-04
NCT07901764
MYTP01 for Immune-Mediated Diseases
Trial Treatment · Zhejiang Provincial People's Hospital
Zhejiang Provincial People's Hospital, Hangzhou
Registry updated 2026-11-04
NCT05517980
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Trial Treatment · Phase 2 · Kira Pharmacenticals (US), LLC.
Peking University First Hospital, Beijing
Registry updated 2026-11-03
NCT07897240
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
Trial Treatment · Phase 1 · Triastek, lnc.
The Second Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-10-27
NCT07888335
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
Trial Treatment · Phase 4 · Ruijin Hospital
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-10-22
NCT07146906
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Trial Treatment · Phase 2 · Novartis Pharmaceuticals
Beijing · Shanghai
Registry updated 2026-10-21
NCT07886476
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Trial Treatment · Phase 1 · Innovent Biologics (Suzhou) Co. Ltd.
Peking University First Hospital, Beijing
Registry updated 2026-10-21
NCT07498335
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Beijing
Registry updated 2026-10-15
NCT06935357
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Trial Treatment · Phase 3 · Biogen
Beijing Tsinghua Changgung Hospital, Beijing · Peking University First Hospital - Changqiao Campus, Beijing · Cangzhou Central Hospital, Cangzhou · Sichuan Academy of Medical Sciences sichuan Provincial People's Hospital, Chengdu · Daqing Oilfield General Hospital, Daqing · Fu Yang People's Hospital - South Campus, Fuyang · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen Memorial Hospital, Sun Yat-sen University - North Campus, Guangzhou · The First Affiliated Hospital of Guangzhou Medical University - Yanjiang Campus, Guangzhou · The Affiliated Hospital of Guizhou Medical University, Guiyang · Guizhou Provincial People's Hospital, Guiyang · The First Affiliated Hospital of Anhui Medical University - Jixilu Campus, Hefei · Prince of Wales Hospital - Hong Kong, Hong Kong · Tung Wah Hospital, Hong Kong · Queen Mary Hospital PPDS, Hong Kong · The Second Hospital of Shandong University, Jinan · Qilu Hospital of Shandong University, Jinan · Jinhua Municipal Central Hospital, Jinhua · Gansu Provincial Hospital, Lanzhou · The First Affiliated Hospital of Henan Science and Technology University - Jinghua Campus, Luoyang · The Second Affiliated Hospital of Nanjing Medical University, Nanjing · The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning · The First Affiliated Hospital of Guangxi Medical University, Nanning · Affiliated Hospital of Nantong University, Nantong · Zhongshan Hospital,Fudan University, Shanghai · Jiading Central Hospital, Shanghai · Shanghai General Hospital - North Campus, Shanghai · Huashan Hospital Fudan University - PPDS, Shanghai · Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang · Peking University Shenzhen Hospital, Shenzhen · Shenzhen Hospital of Southern Medical University, Shenzhen · The Third Hospital of Hebei Medical University, Shijiazhuang · The Second Hospital of Hebei Medical University - Main, Shijiazhuang · Taizhou Hospital of Zhejiang Province - Main, Taizhou · Renmin Hospital of Wuhan University - Main Campus, Wuhan · Wuxi Peoples Hospital, Wuxi · Zhongshan Hospital Xiamen University, Xiamen · Yantai Yuhuangding Hospital, Yantai · Yichang Central People's Hospital - Wujiagang Campus, Yichang · Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan
Registry updated 2026-10-14
NCT04557462
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Beijing · Changchun · Changsha · Guangzhou · Luoyang · Ningbo · Qingdao · Shanghai · Shenzhen · Taiyuan · Ürümqi · Wenzhou · Xian · Yinchuan · Zhengzhou
Registry updated 2026-10-05
NCT07822100
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
Trial Treatment · Hong Zhang
Peking University First Hospital, Beijing
Registry updated 2026-09-16
NCT03001947
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Research · Sun Yat-sen University
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
Registry updated 2026-09-15
NCT05190848
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Research · Guangdong Provincial People's Hospital
The Third Affiliated Hospital of Southern Medical University, Guangzhou · Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou · The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou · The First Affiliated Hospital of Sun Yat-sen University, Guanzhou · Guangdong Provincial People's Hospital, Guanzhou
Registry updated 2026-09-14
NCT07389499
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Trial Treatment · Early phase 1 · Grit Biotechnology
Zhongshan Hospital Affiliated to Fudan University, Shanghai
Registry updated 2026-09-11
NCT06994845
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Beijing · Hangzhou
Registry updated 2026-09-09
NCT07522099
Chinese Adults With Kidney Disease
Trial Treatment · Phase 2 · ADARx Pharmaceuticals, Inc.
Baotou · Beijing · Guiyang · Shandong · Shanghai · Shenzhen · Wuxi · Yantai · Zhengzhou
Registry updated 2026-09-03
NCT07604311
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
Trial Treatment · Phase 4 · Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University, Guangzhou
Registry updated 2026-09-02
NCT04858724
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Research · Ruijin Hospital
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai
Registry updated 2026-08-18
NCT07746453
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
Trial Treatment · Guangdong Provincial People's Hospital
Guangdong Provincial People'S Hospital, Guangdong
Registry updated 2026-08-10
NCT07614477
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Trial Treatment · Phase 2 · Everest Medicines (China) Co.,Ltd.
Peking University First Hospital, Beijing · Tianjin Medical University General Hospital, Tianjin
Registry updated 2026-08-05
NCT07203404
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Trial Treatment · Early phase 1 · Nanjing Bioheng Biotech Co., Ltd.
Zhongshan Hospital,Fudan University, Shanghai
Registry updated 2026-08-03
NCT07024563
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Trial Treatment · Phase 3 · Alexion Pharmaceuticals, Inc.
Beijing · Shanghai
Registry updated 2026-07-30
NCT07730632
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
Trial Treatment · Phase 2 · Qilu Pharmaceutical Co., Ltd.
Peking University First Hospital, Beijing
Registry updated 2026-07-28
NCT07582133
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Trial Treatment · Phase 2 · Chengdu Suncadia Medicine Co., Ltd.
Peking University First Hospital, Beijing
Registry updated 2026-07-22
NCT07674147
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Trial Treatment · Early phase 1 · The Children's Hospital of Zhejiang University School of Medicine
Children's Hospital, Zhejiang University School of Medicine, Hangzhou · Nanjing Children's Hospital, Nanjing
Registry updated 2026-06-29

All IgA nephropathy trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error